PALO ALTO, Calif., June 11, 2025--(BUSINESS WIRE)--Vivo Capital ("Vivo" or "we"), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% ...

Like you, we are shareholders in Sinovac Biotech Ltd. ("Sinovac" or the "Company"). Heng Ren Partners, LLC ("Heng Ren") manages funds that have held Sinovac shares since 2018. Heng Ren has long ...

KATHMANDU - Nepal's drug regulator has approved the COVID-19 vaccine developed by Chinese pharmaceutical company Sinovac ...

A study in China found that SinoVac and SinoPharm were 70% effective in preventing COVID-19 infection A preprint study in Brazil found that SinoVac was only 54% effective in preventing coronavirus ...

Add Yahoo as a preferred source to see more of our stories on Google. China's Sinovac COVID-19 vaccines produced by VACSERA Co. are seen in Cairo JOHANNESBURG (Reuters) -China's Sinovac Biotech will ...

Sinovac's COVID-19 vaccine was an estimated 98% effective at preventing death in Indonesian health workers. It was also 96% effective at preventing hospitalization, Indonesian officials said. The data ...

The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) today announced several important decisions to deliver sustainable value to shareholders and strengthen the Company’s governance framework.

If you’d asked Dani a few months ago which COVID-19 vaccine she was getting, she probably would have said the same as most other Filipinos: Sinovac. Until as recently as May, the Chinese-made ...

Corrects the Company’s Misrepresentations of Vivo’s Capital Contributions, Which Have Been Critical to Sinovac’s Commercial Success and Ability to Return Capital to Shareholders Calls on All ...